APLS
Apellis Pharmaceuticals Inc

3,680
Mkt Cap
$2.2B
Volume
5.6M
52W High
$30.48
52W Low
$16.10
PE Ratio
139.35
APLS Fundamentals
Price
$17.21
Prev Close
$17.97
Open
$17.96
50D MA
$21.38
Beta
1.03
Avg. Volume
2.17M
EPS (Annual)
$0.1724
P/B
5.89
Rev/Employee
$1.36M
$3,268.56
Loading...
Loading...
News
all
press releases
Apellis Pharmaceuticals, Inc. $APLS Holdings Cut by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP cut its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 11.9% in the 3rd quarter, according to its most recent Form 13F filing with...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Cantor Fitzgerald Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price
Cantor Fitzgerald dropped their target price on shares of Apellis Pharmaceuticals from $35.00 to $31.00 and set an "overweight" rating for the company in a research report on Wednesday...
MarketBeat·3d ago
News Placeholder
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS
Bank of Nova Scotia raised its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 144.8% in the third quarter, according to the company in its most recent Form 13F...
MarketBeat·5d ago
News Placeholder
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC
HighVista Strategies LLC increased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Free Report) by 68.2% in the third quarter, according to the company in its most recent 13F...
MarketBeat·6d ago
News Placeholder
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages
Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) have received a consensus rating of "Moderate Buy" from the twenty-two ratings firms that are presently covering the firm...
MarketBeat·6d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm
Roth Mkm initiated coverage on Apellis Pharmaceuticals in a research note on Friday. They set a "buy" rating and a $31.00 price objective on the stock...
MarketBeat·8d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co.
JPMorgan Chase & Co. raised their target price on Apellis Pharmaceuticals from $36.00 to $37.00 and gave the stock an "overweight" rating in a research report on Thursday...
MarketBeat·16d ago
News Placeholder
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho
Mizuho upped their price objective on shares of Apellis Pharmaceuticals from $19.00 to $20.00 and gave the company a "neutral" rating in a report on Thursday...
MarketBeat·16d ago
News Placeholder
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts
read more...
Benzinga·16d ago
News Placeholder
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.
Apellis Pharmaceuticals (NASDAQ:APLS) executives outlined a three-part strategy for the company at TD Cowen's 46th Annual Healthcare Conference, emphasizing a durable and resilient SYFOVRE franchise...
MarketBeat·19d ago
<
1
2
...
>

Latest APLS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.